Active, Not Recruiting
The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR
NCT02493582
- Conditions
- Adenocarcinoma, Adenocarcinoma of Lung, Carcinoma, +7 more
- Locations
-
Not specified